CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, a biopharmaceutical company leveraging the therapeutic potential of omega-3 fatty acids and other well-characterized compounds to create dual action medicines for the treatment of inflammatory and metabolic diseases, today announced the appointment of Lucienne V. Ronco, Ph.D., to the newly created position of vice president, research. In addition, the company announced the appointment of leading experts to its newly formed clinical advisory board. These appointments will support the continued growth of the company and signify progress made in advancing the company’s rich pipeline of omega-3 conjugated compounds, which have the potential to treat a range of metabolic and inflammatory diseases.
